CN103356571A - Application of Sarcaboside B in preparation of medicines for treating nasopharynx cancer - Google Patents
Application of Sarcaboside B in preparation of medicines for treating nasopharynx cancer Download PDFInfo
- Publication number
- CN103356571A CN103356571A CN 201310265181 CN201310265181A CN103356571A CN 103356571 A CN103356571 A CN 103356571A CN 201310265181 CN201310265181 CN 201310265181 CN 201310265181 A CN201310265181 A CN 201310265181A CN 103356571 A CN103356571 A CN 103356571A
- Authority
- CN
- China
- Prior art keywords
- sarcaboside
- preparation
- medicines
- nasopharynx cancer
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of Sarcaboside B in the preparation of medicines for treating nasopharynx cancer, belonging to the technical field of new applications of medicines. The evaluation on the anti-tumor activity of the Sarcaboside B by an MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) method in vitro shows that the Sarcaboside B aslo has an obvious inhibiting effect on the growth of human nasopharynx cancer cell strains HNE1, HNE2, HONE1 and CNE1. Therefore, the Sarcaboside B can be used for the preparation of anti-nasopharynx cancer medicines and has good development and application prospects. The application of the Sarcaboside B in the preparation of the medicines for treating the nasopharynx cancer is disclosed by the invention for the first time. As the skeleton type of the Sarcaboside B belongs to a brand-new skeleton type, the Sarcaboside B has unexpected strong inhibitory activity on nasopharynx cancer cells.
Description
Technical field
The present invention relates to the new purposes of compound S arcaboside B, relate in particular to the application of Sarcaboside B in the anti-medicine for nasopharyngeal of preparation.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound S arcaboside B that the present invention relates to is one and delivered (Li in 2012, X. et al., 2012. Two New-Skeleton Compounds from Sarcandra glabra. Helvetica Chimica Acta 95 (6), 998-1002.) New skeleton compound, this chemical compound has brand-new framework types, there is not at present the report about activity, belong to open first for the purposes of the Sarcaboside B that the present invention relates in preparation treatment medicine for nasopharyngeal, because framework types belongs to brand-new framework types, and its inhibition for nasopharyngeal carcinoma cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously nasopharyngeal carcinoma obviously has significant progress.
Summary of the invention
The invention provides the application of compound S arcaboside B in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Sarcaboside B in the anti-medicine for nasopharyngeal of preparation, and the structural formula of Sarcaboside B is shown in formula I:
Formula I
The present invention finds that by external MTT anti-tumor activity evaluation Sarcaboside B also has significant inhibitory action to the growth of human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1, suppresses the IC of this 4 strain Growth of Cells
50Value is respectively 1.16 ± 0.07 μ M, 1.48 ± 0.29 μ M, 2.06 ± 0.27 μ M and 3.48 ± 0.49 μ M.Therefore, Sarcaboside B can for the preparation of anti-medicine for nasopharyngeal, have good development prospect.
Belong to open first for the purposes of the Sarcaboside B that the present invention relates in preparation treatment medicine for nasopharyngeal, because framework types belongs to brand-new framework types, and its inhibition for nasopharyngeal carcinoma cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously nasopharyngeal carcinoma obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound S arcaboside B involved in the present invention is referring to document (Li, X. et al., 2012. Two New-Skeleton Compounds from Sarcandra glabra. Helvetica Chimica Acta 95 (6), 998-1002.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound S arcaboside B tablet involved in the present invention:
Get 20 and digest compound Sarcaboside B, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound S arcaboside B capsule involved in the present invention:
Get 20 and digest compound Sarcaboside B, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Sarcaboside B to the growth inhibited effect of human nasopharyngeal carcinoma cell line
1. method: the cell that is in the growth logarithmic (log) phase: human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Sarcaboside B of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Sarcaboside B has significant inhibitory action to the growth of human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1.This chemical compound suppresses the IC of human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1 growth
50Value is respectively: 1.16 ± 0.07 μ M, 1.48 ± 0.29 μ M, 2.06 ± 0.27 μ M and 3.48 ± 0.49 μ M.
Shown that by above-described embodiment Sarcaboside B of the present invention has good inhibitory action to the growth of human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1.Prove that thus it is active that Sarcaboside B of the present invention has anti-nasopharyngeal carcinoma, can be for the preparation of anti-medicine for nasopharyngeal.
Claims (1)
1.Sarcaboside B is in the application for the treatment of in the medicine for nasopharyngeal, described compound S arcaboside B structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310265181 CN103356571A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside B in preparation of medicines for treating nasopharynx cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310265181 CN103356571A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside B in preparation of medicines for treating nasopharynx cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103356571A true CN103356571A (en) | 2013-10-23 |
Family
ID=49359393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201310265181 Pending CN103356571A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside B in preparation of medicines for treating nasopharynx cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103356571A (en) |
-
2013
- 2013-06-27 CN CN 201310265181 patent/CN103356571A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103405418A (en) | Application of Chukrasone B in medicine for treating breast cancer | |
| CN103356571A (en) | Application of Sarcaboside B in preparation of medicines for treating nasopharynx cancer | |
| CN103371996A (en) | Application of Sarcaboside A in medicine for treating nasopharynx cancer | |
| CN103356585A (en) | Application of Sarcaboside B in preparation of medicines for treating bladder cancer | |
| CN103356559A (en) | Application of Sarcaboside B in preparation of medicines for treating tongue cancer | |
| CN103356552A (en) | Application of Sarcaboside B in preparation of medicines for treating endometrial cancer | |
| CN103356530A (en) | Application of Sarcaboside B in preparation of medicines for treating ileocecum cancer | |
| CN103356557A (en) | Application of Sarcaboside B in preparation of medicines for treating liver cancer | |
| CN103356545A (en) | Application of Sarcaboside B in medicine used for treating ovarian cancer | |
| CN103405451A (en) | Application of Chukrasone A in medicaments for treating tongue carcinoma | |
| CN103356560A (en) | Application of Sarcaboside B in medicine used for treating prostate cancer | |
| CN103356538A (en) | Application of Sarcaboside A in preparation of drug for treating ovarian cancer | |
| CN103356553A (en) | Application of Sarcaboside A in preparation of drug for treating breast cancer | |
| CN103356534A (en) | Application of Sarcaboside B in medicine used for treating colorectal cancer | |
| CN103405447A (en) | Application of Chukrasone A in medicaments for treating nasopharyngeal carcinoma | |
| CN103356550A (en) | Application of Sarcaboside B in medicine used for treating laryngeal cancer | |
| CN103356577A (en) | Application of Sarcaboside A in preparation of drug for treating stomach cancer | |
| CN103356589A (en) | Application of Sarcaboside A in preparation of drug for treating cervical cancer | |
| CN103356541A (en) | Application of Sarcaboside B in medicine used for treating gastric cancer | |
| CN103356532A (en) | Application of Sarcaboside B in medicine used for treating breast cancer | |
| CN103405421A (en) | Application of Chukrasone B in medicine for treating cervical cancer | |
| CN103463069A (en) | Application of Lycojaponicumin C in preparation of medicines for treating nasopharynx cancer | |
| CN103405420A (en) | Application of Chukrasone B in medicine for treating nasopharynx cancer | |
| CN103356539A (en) | Application of Sarcaboside A in preparation of drug for treating colorectal cancer | |
| CN103405449A (en) | Application of Chukrasone A in medicaments for treating breast carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131023 |